Novartis heart-drug trial drops stock

A drug trial by Novo Nordisk, believed to target the reduction of heart attack and stroke risk, has failed. A large clinical study showed that the medication did not decrease cardiovascular risks despite lowering the levels of the targeted protein. The results, which involved over 6,300 people, revealed an increased incidence of serious infections, leading to a drop in the company’s shares by up to 10.5%, the largest decline in months. Despite these negative results, the company plans to continue additional trials to assess the drug’s impact on heart failure and acute events, with new results expected to be announced in the first half of next year.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل